Menu Search
Equities

Artgen Biotekh PAO

ABIO:MCX

Artgen Biotekh PAO

Actions
  • Price (RUB)110.22
  • Today's Change-0.36 / -0.33%
  • Shares traded202.16k
  • 1 Year change+5.41%
  • Beta--
Data delayed at least 30 minutes, as of May 10 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Institut Stvolovykh Kletok Cheloveka PAO (Human Stem Cells Institute OJSC or HSCI OJSC) is a Russia-based company engaged in the research and development, as well as commercialization and marketing of proprietary products and services in the areas of cell-based and gene and post-genome technologies. The Company is engaged in such projects as: Gemabank, cord blood stem cells bank; Gemascreen medical genetic diagnostics and consulting services provided by the Company domestically with the aim of early detection, treatment or prevention of inherited diseases; SPRS-therapy service a set of personalized diagnostics and treatment procedures; SynBio, which focuses on development of new medicines. In addition, the Company is a producer of Neovasculgen, a gene-therapy drug. In February 2014, it opened a biotech complex in Kyiv.

  • Revenue in RUB (TTM)1.37bn
  • Net income in RUB168.86m
  • Incorporated2003
  • Employees--
  • Location
    Artgen Biotekh PAOul Gubkina, d. 3, k. 1, pomeshch. 1/1MOSCOW 119333Russian FederationRUS
  • Phone+7 4 956468076
  • Fax+7 4 956468076
  • Websitehttps://artgen.ru/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.